Skip to content

Author

Paul Zimmer-Harwood

We have 1 of 5 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Cost-benefit analysis of a potential hepatitis C vaccine: a modelling study.

In the context of heterogeneous treatment scale-up among countries, a hepatitis C vaccine is likely to have a positive return-on-investment when used to vaccinate populations at highest risk of infection.

Farah Houdroge, Phillip Luong, Jessica Zuk et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.